ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
Borealisbio
Borealis Bio is inviting individuals to submit a general application for potential future employment. This allows the company to review qualifications and consider candidates when relevant positions become available.
Borealis Biosciences is a biotech company developing RNA medicines that selectively target kidney cells to treat chronic kidney diseases with large unmet need. Founded by an experienced drug‑discovery team (building on the Chinook Therapeutics group acquired by Novartis), Borealis combines targeted RNA delivery, translational systems biology, data science, chemistry, DMPK and pharmacology to pursue validated causal targets not addressable by traditional small molecules or biologics. Backed by Versant Ventures, Novartis and Westlake Bio, the company launched with a $150M Series A and is headquartered in Vancouver, BC.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Borealisbio.
Borealisbio didn’t post a salary, so this is our estimate from similar listings.